VivoSeq
Immunology

Rheumatoid Arthritis

673

Pipeline Programs↗

121

Active Trials↗

166

Companies Involved↗

Rheumatoid Arthritis is a highly competitive landscape with 673 programs across 166 companies. The most active players are Daiichi Sankyo, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Candid Therapeutics. 92 therapies are approved with 132 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

99/100

Pipeline Velocity

64/100

Mech. Concentration

8/100

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Daiichi Sankyo logo

Daiichi Sankyo

2 programs

Phase 1P

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

2 programs

Phase 1C

Candid Therapeutics

2 programs

Phase 1L

Lexicon Pharmaceuticals

1 program

Phase 1M

Modern Biosciences Ltd

1 program

Phase 1I

IGM Biosciences, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

591 of 692 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody588%Protein / enzyme183%Cell therapy142%Vaccine71%Peptide3<1%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 692 classified programs, each share of the total. Modality classified for 99% of 792 pipeline programs.

Analysis

Trial Status

1,336

clinical trials

Completed955 · 71%
Terminated122 · 9%
Unknown status105 · 8%
Recruiting70 · 5%
Withdrawn26 · 2%
Not yet recruiting26 · 2%
Other32 · 2%

Clinical Trials

Trial Activity

1336 trials

HiSCs in the Treatment of Rheumatoid Arthritis
Recruiting·SShanghai Changzheng Hospital·N/A·NCT06947746·15 enrolled
Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis
Recruiting·UUniversity Hospital, Strasbourg, France·Phase 4·NCT06906549·260 enrolled
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
Recruiting·ZZenas BioPharma (USA), LLC·Phase 1·NCT05638854·72 enrolled
Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT06301373·130 enrolled
Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
Recruiting·—·N/A·NCT07089381·118 enrolled
Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)
Recruiting·UUniversita di Verona·Phase 4·NCT06527534·30 enrolled
Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)
Recruiting·UUniversity Hospital, Strasbourg, France·Phase 3·NCT05092984·154 enrolled
Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis
Recruiting·—·Phase 4·NCT05540938·340 enrolled
Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04292067·400 enrolled
Fecal Microbial Transplantation for Rheumatoid Arthritis Trial
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT05790356·30 enrolled
Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis
Recruiting·—·Phase 4·NCT06146972·117 enrolled
A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis
Recruiting·XXencor, Inc.·Phase 1·NCT07230353·47 enrolled
An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT06613490·24 enrolled
Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.
Recruiting·—·N/A·NCT06630715·178 enrolled
Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
Recruiting·LLifordi Immunotherapeutics, Inc.·Phase 1·NCT07207954·176 enrolled
Page 1 of 90

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)